E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10056886 |
E.1.2 | Term | Mucopolysaccharidosis I |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants • To evaluate the efficacy of Aldurazyme on urinary glycosaminoglycans (uGAGs) after 26 weeks of treatment in Chinese MPS I participants
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effect on uGAG level in Chinese MPS I participants • To evaluate liver volume (hepatomegaly) with Aldurazyme treatment in Chinese MPS I participants |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA activity <10% of normal.
Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes.
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP). OR Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention.
A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention.
If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
Contraceptive/barrier method is not applicable for male participants.
|
|
E.4 | Principal exclusion criteria |
Participants are excluded from the study if any of the following criteria apply: Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation. Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment. Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment. Received an investigational gene therapy.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1/ Participants with adverse events (AEs) 2/ The change during the TE period in electrocardiogram (ECG), clinical laboratory parameters (hematology and biochemistry), and vital signs 3/ The percent change of uGAGs |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1/ and 2/: Baseline to Week 27 3/: Baseline to Week 26 |
|
E.5.2 | Secondary end point(s) |
1/ The percent change of uGAGs 2/ The absolute change of uGAGs 3/ The percent change of liver volume (Abdominal B type ultrasound examination)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1/ and 2/: Baseline to Week 2, Week 4, Week 8, Week 12 and Week 20 3/: Baseline to Week 26
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |